Patent intelligence · US
US 7057029
Human ion-exchanger proteins
Human ion-exchanger proteins
Patent details — US 7057029
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 6, 2006
- Expiration
- Jun 1, 2026
- Applicant
- Lexicon Genetics, Inc.
- Claims
- 1
- CPC classes
- A61K, A61K38/00
Quick answer
US 7057029 (Human ion-exchanger proteins) is held by Lexicon Genetics, Inc.. Status: granted. Granted Jun 6, 2006. Expires Jun 1, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Lexicon Genetics, Inc.
- Grant date
- Expiration
- Claims
- 1
- CPC classes
- A61K, A61K38/00
More from Lexicon Genetics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12344596
Solid forms of (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof
granted -
US 11730723
Compounds and methods for treating viral infections
granted -
US 11666575
Pyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections
granted -
US 11059907
Antibodies that bind Notum Pectinacetylesterase
granted -
US 10106569
Inhibitors of sodium glucose transporter 1 for constipation
granted -
US 9862724
Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
granted -
US 9688710
Inhibitors of sodium glucose cotransporter 1
granted -
US 9682982
Inhibitors of adapter associated kinase 1, compositions comprising them, and methods of their use
granted
Frequently asked questions
What is US patent 7057029?
US 7057029 (Human ion-exchanger proteins) is held by Lexicon Genetics, Inc.. Status: granted. Granted Jun 6, 2006. Expires Jun 1, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7057029?
Lexicon Genetics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 102 pharmaceutical patents for this assignee.
When does US 7057029 expire?
Our index shows an expiration date of Jun 1, 2026 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.